Literature DB >> 20132973

CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

Esther Morel1, Salvador Escamochero, Rosario Cabañas, Rosa Díaz, Ana Fiandor, Teresa Bellón.   

Abstract

BACKGROUND: Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are severe, bullous cutaneous diseases with uncertain pathogenesis, although cytotoxic T cells seem to be involved. Natural killer (NK)-like activity has been found in blister infiltrates. Cytotoxic T lymphocytes (CTLs) with NK-like activity (NK-CTLs) have been shown to express T-cell receptors restricted by the HLA-Ib molecule HLA-E. Alternatively, the HLA-E-specific activating receptor CD94/NKG2C can trigger T-cell receptor-independent cytotoxicity in CTLs.
OBJECTIVE: Our aim was to test whether HLA-E expression sensitizes keratinocytes to killing by CTLs with NK-like activity and to explore the expression of activating receptors specific for HLA-E in blister cytotoxic lymphocytes.
METHODS: We used flow cytometry and immunohistochemistry to analyze HLA-E expression in keratinocytes from affected skin in patients with SJS, TEN, and other less severe drug-induced exanthemas. The expression of CD94/NKG2C was analyzed by means of flow cytometry in PBMCs and blister cells from patients. PBMCs and blister cells were analyzed for their ability to kill HLA-E-expressing cells. Involvement of CD94/NKG2C in triggering degranulation of cytolytic cells was explored by means of CD107a mobilization assays and standard cytotoxicity chromium release assays.
RESULTS: We found that keratinocytes from affected skin expressed HLA-E and that cell-surface HLA-E sensitizes keratinocytes to killing by CD94/NKG2C(+) CTLs. Frequencies of CD94/NKG2C(+) peripheral blood T and NK cells were increased in patients with SJS and TEN during the acute phase. Moreover, activated blister T and NK lymphocytes expressed CD94/NKG2C and were able to degranulate in response to HLA-E(+) cells in an NKG2C-dependent manner.
CONCLUSION: CD94/NKG2C might be involved in triggering cytotoxic lymphocytes in patients with SJS and TEN.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20132973     DOI: 10.1016/j.jaci.2009.10.030

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  17 in total

Review 1.  Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.

Authors:  S Shahzad Mustafa; David Ostrov; Daniel Yerly
Journal:  Curr Allergy Asthma Rep       Date:  2018-03-24       Impact factor: 4.806

2.  Deletion of the activating NKG2C receptor and a functional polymorphism in its ligand HLA-E in psoriasis susceptibility.

Authors:  Xue Zeng; Haoyan Chen; Rashmi Gupta; Oscar Paz-Altschul; Anne M Bowcock; Wilson Liao
Journal:  Exp Dermatol       Date:  2013-10       Impact factor: 3.960

Review 3.  Recent advances in the understanding of severe cutaneous adverse reactions.

Authors:  N R Adler; A K Aung; E N Ergen; J Trubiano; M S Y Goh; E J Phillips
Journal:  Br J Dermatol       Date:  2017-09-29       Impact factor: 9.302

4.  Toxic epidermal necrolysis - management issues and treatment options.

Authors:  Alan D Widgerow
Journal:  Int J Burns Trauma       Date:  2011-09-03

5.  Recent progress of elucidating the mechanisms of drug hypersensitivity.

Authors:  Hideo Hashizume
Journal:  Asia Pac Allergy       Date:  2012-07-25

6.  Acute compartment syndrome of the forearm as a rare complication of toxic epidermal necrolysis: a case report.

Authors:  Tamer Kamal; Sherif Elnikety; Heba Mashaly; James Casha
Journal:  J Med Case Rep       Date:  2012-03-20

Review 7.  Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances.

Authors:  Teresa Bellón
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.228

Review 8.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

Review 9.  Bullous Drug Reactions.

Authors:  Maja Mockenhaupt
Journal:  Acta Derm Venereol       Date:  2020-02-12       Impact factor: 3.875

Review 10.  Immunopharmacogenomics: Mechanisms of HLA-Associated Drug Reactions.

Authors:  Pooja Deshpande; Rebecca J Hertzman; Amy M Palubinsky; Jason B Giles; Jason H Karnes; Andrew Gibson; Elizabeth J Phillips
Journal:  Clin Pharmacol Ther       Date:  2021-07-17       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.